Evaluation of lymphocyte apoptosis in patients with oral cancer

Detalhes bibliográficos
Autor(a) principal: BIN-ALEE,Fardeela
Data de Publicação: 2020
Outros Autores: ARAYATAWEEGOOL,Areeya, BURANAPRADITKUN,Supranee, MAHATTANASAKUL,Patnarin, TANGJATURONRASME,Napadon, MUTIRANGURA,Apiwat, KITKUMTHORN,Nakarin
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Journal of applied oral science (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1678-77572020000100467
Resumo: Abstract Objectives To evaluate apoptotic levels of peripheral blood mononuclear cells (PBMCs) and apoptotic regulatory proteins (Bax and Bcl-2) in lymphocyte subsets of oral cancer (OC) patients and healthy controls (HC). Methodology The percentage of apoptotic cells and lymphocyte counts were measured in the first cohort using PBMCs obtained from 23 OC patients and 6 HC. In the second cohort, (OC, 33; HC, 13), the mean fluorescence intensity (MFI) of Bax and Bcl-2 in CD19+ B, CD4+ T, CD8+ T, and CD16+56+ natural killer (NK) cells was determined via flow cytometry. Results The percentage of apoptotic cells was higher in the PBMCs of OC patients than in HC patients, particularly in patients with stage IV cancer (p<0.05). However, lymphocyte counts were significantly lower in stage IV patients (p<0.05). NK CD19+ B and CD16+56+ cell counts were significantly lower in OC patients compared with HC patients (p<0.001 and p<0.01, respectively), but CD4+ T cells were interestingly significantly higher in OC patients (p<0.001). While Bax MFI was slightly higher, Bcl-2 MFI was significantly lower for all four lymphocyte subsets in OC samples, particularly in stage IV patients, when compared with HC. Consequently, Bax/Bcl-2 ratios showed an upward trend from HC to OC patients, particularly those in stage IV. We found similar trends in Bax and Bcl-2 MFI for tumor stage, tumor size, and lymph node involvement. Conclusions The increased lymphocyte apoptosis in stage IV OC patients may be related to higher Bax levels and lower Bcl-2 levels. The Bax/Bcl-2 ratio in lymphocytes may be useful to determine the prognosis of OC patients, and could be considered a mean for supportive treatment in the future.
id USP-17_c10552c08276e4d5c3baac7300e190a8
oai_identifier_str oai:scielo:S1678-77572020000100467
network_acronym_str USP-17
network_name_str Journal of applied oral science (Online)
repository_id_str
spelling Evaluation of lymphocyte apoptosis in patients with oral cancerApoptosisBax/Bcl-2LymphocyteOral cancerNeoplasm stagingAbstract Objectives To evaluate apoptotic levels of peripheral blood mononuclear cells (PBMCs) and apoptotic regulatory proteins (Bax and Bcl-2) in lymphocyte subsets of oral cancer (OC) patients and healthy controls (HC). Methodology The percentage of apoptotic cells and lymphocyte counts were measured in the first cohort using PBMCs obtained from 23 OC patients and 6 HC. In the second cohort, (OC, 33; HC, 13), the mean fluorescence intensity (MFI) of Bax and Bcl-2 in CD19+ B, CD4+ T, CD8+ T, and CD16+56+ natural killer (NK) cells was determined via flow cytometry. Results The percentage of apoptotic cells was higher in the PBMCs of OC patients than in HC patients, particularly in patients with stage IV cancer (p<0.05). However, lymphocyte counts were significantly lower in stage IV patients (p<0.05). NK CD19+ B and CD16+56+ cell counts were significantly lower in OC patients compared with HC patients (p<0.001 and p<0.01, respectively), but CD4+ T cells were interestingly significantly higher in OC patients (p<0.001). While Bax MFI was slightly higher, Bcl-2 MFI was significantly lower for all four lymphocyte subsets in OC samples, particularly in stage IV patients, when compared with HC. Consequently, Bax/Bcl-2 ratios showed an upward trend from HC to OC patients, particularly those in stage IV. We found similar trends in Bax and Bcl-2 MFI for tumor stage, tumor size, and lymph node involvement. Conclusions The increased lymphocyte apoptosis in stage IV OC patients may be related to higher Bax levels and lower Bcl-2 levels. The Bax/Bcl-2 ratio in lymphocytes may be useful to determine the prognosis of OC patients, and could be considered a mean for supportive treatment in the future.Faculdade De Odontologia De Bauru - USP2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1678-77572020000100467Journal of Applied Oral Science v.28 2020reponame:Journal of applied oral science (Online)instname:Universidade de São Paulo (USP)instacron:USP10.1590/1678-7757-2020-0124info:eu-repo/semantics/openAccessBIN-ALEE,FardeelaARAYATAWEEGOOL,AreeyaBURANAPRADITKUN,SupraneeMAHATTANASAKUL,PatnarinTANGJATURONRASME,NapadonMUTIRANGURA,ApiwatKITKUMTHORN,Nakarineng2020-09-03T00:00:00Zoai:scielo:S1678-77572020000100467Revistahttp://www.scielo.br/jaosPUBhttps://old.scielo.br/oai/scielo-oai.php||jaos@usp.br1678-77651678-7757opendoar:2020-09-03T00:00Journal of applied oral science (Online) - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Evaluation of lymphocyte apoptosis in patients with oral cancer
title Evaluation of lymphocyte apoptosis in patients with oral cancer
spellingShingle Evaluation of lymphocyte apoptosis in patients with oral cancer
BIN-ALEE,Fardeela
Apoptosis
Bax/Bcl-2
Lymphocyte
Oral cancer
Neoplasm staging
title_short Evaluation of lymphocyte apoptosis in patients with oral cancer
title_full Evaluation of lymphocyte apoptosis in patients with oral cancer
title_fullStr Evaluation of lymphocyte apoptosis in patients with oral cancer
title_full_unstemmed Evaluation of lymphocyte apoptosis in patients with oral cancer
title_sort Evaluation of lymphocyte apoptosis in patients with oral cancer
author BIN-ALEE,Fardeela
author_facet BIN-ALEE,Fardeela
ARAYATAWEEGOOL,Areeya
BURANAPRADITKUN,Supranee
MAHATTANASAKUL,Patnarin
TANGJATURONRASME,Napadon
MUTIRANGURA,Apiwat
KITKUMTHORN,Nakarin
author_role author
author2 ARAYATAWEEGOOL,Areeya
BURANAPRADITKUN,Supranee
MAHATTANASAKUL,Patnarin
TANGJATURONRASME,Napadon
MUTIRANGURA,Apiwat
KITKUMTHORN,Nakarin
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv BIN-ALEE,Fardeela
ARAYATAWEEGOOL,Areeya
BURANAPRADITKUN,Supranee
MAHATTANASAKUL,Patnarin
TANGJATURONRASME,Napadon
MUTIRANGURA,Apiwat
KITKUMTHORN,Nakarin
dc.subject.por.fl_str_mv Apoptosis
Bax/Bcl-2
Lymphocyte
Oral cancer
Neoplasm staging
topic Apoptosis
Bax/Bcl-2
Lymphocyte
Oral cancer
Neoplasm staging
description Abstract Objectives To evaluate apoptotic levels of peripheral blood mononuclear cells (PBMCs) and apoptotic regulatory proteins (Bax and Bcl-2) in lymphocyte subsets of oral cancer (OC) patients and healthy controls (HC). Methodology The percentage of apoptotic cells and lymphocyte counts were measured in the first cohort using PBMCs obtained from 23 OC patients and 6 HC. In the second cohort, (OC, 33; HC, 13), the mean fluorescence intensity (MFI) of Bax and Bcl-2 in CD19+ B, CD4+ T, CD8+ T, and CD16+56+ natural killer (NK) cells was determined via flow cytometry. Results The percentage of apoptotic cells was higher in the PBMCs of OC patients than in HC patients, particularly in patients with stage IV cancer (p<0.05). However, lymphocyte counts were significantly lower in stage IV patients (p<0.05). NK CD19+ B and CD16+56+ cell counts were significantly lower in OC patients compared with HC patients (p<0.001 and p<0.01, respectively), but CD4+ T cells were interestingly significantly higher in OC patients (p<0.001). While Bax MFI was slightly higher, Bcl-2 MFI was significantly lower for all four lymphocyte subsets in OC samples, particularly in stage IV patients, when compared with HC. Consequently, Bax/Bcl-2 ratios showed an upward trend from HC to OC patients, particularly those in stage IV. We found similar trends in Bax and Bcl-2 MFI for tumor stage, tumor size, and lymph node involvement. Conclusions The increased lymphocyte apoptosis in stage IV OC patients may be related to higher Bax levels and lower Bcl-2 levels. The Bax/Bcl-2 ratio in lymphocytes may be useful to determine the prognosis of OC patients, and could be considered a mean for supportive treatment in the future.
publishDate 2020
dc.date.none.fl_str_mv 2020-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1678-77572020000100467
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1678-77572020000100467
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1678-7757-2020-0124
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Faculdade De Odontologia De Bauru - USP
publisher.none.fl_str_mv Faculdade De Odontologia De Bauru - USP
dc.source.none.fl_str_mv Journal of Applied Oral Science v.28 2020
reponame:Journal of applied oral science (Online)
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Journal of applied oral science (Online)
collection Journal of applied oral science (Online)
repository.name.fl_str_mv Journal of applied oral science (Online) - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||jaos@usp.br
_version_ 1748936440861949952